Krystal Biotech, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Krystal Biotech, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 113.4 times by its yearly operating cash. Higher than 97% of Healthcare companies in United States.
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 8.4 times. Higher than 94% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
$77Over the last 3 years, every $100 of reported profit came with $77 of operating cash.
Lower than 91% of Healthcare companies in United States.
Self-Funding Ratio
8.4×Over the last 3 years its own operating cash covered its investment spending (capex) 8.4 times.
Higher than 94% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
113.4×Debt due within a year is covered 113.4 times by its yearly operating cash.
Higher than 97% of Healthcare companies in United States.
Cash Cushion Ratio
+9%Cash, after subtracting all debt, equals 9% of its market value (net cash).
Lower than 52% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Krystal Biotech, Inc. owes $0.09 for every $1 it owns. Net profit rose 130% in the year to Dec 2025.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
40.1Investors pay $40.1 for every $1 of Krystal Biotech, Inc.'s yearly profit, higher than 73% of Healthcare companies in United States.
P/B ratio
6.97The share price is 6.97 times Krystal Biotech, Inc.'s book value per share, higher than 80% of Healthcare companies in United States.
Market cap
$9.5 BThe total market value of all of Krystal Biotech, Inc.'s shares at today's price (share price × number of shares), larger than 89% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$1.4 BWhat Krystal Biotech, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$45.92Net worth divided by the number of shares. The share price of $320.13 is 7.0 times this, which is the P/B above.
Return on equity (ROE)
20.1%Krystal Biotech, Inc. earned 20.1% on its shareholders' money over the last year, higher than 90% of Healthcare companies in United States.
Owes vs Owns
0.09×Krystal Biotech, Inc. owes $0.09 for every $1 it owns (low), lower than 88% of Healthcare companies in United States.
Dividend yield
NoneKrystal Biotech, Inc. does not currently pay a dividend.
Revenue growth
+34%Revenue rose 34% in the year to Dec 2025.
Profit growth
+130%Net profit rose 130% in the year to Dec 2025.
Profit margin
52.6%Krystal Biotech, Inc. keeps $53 of every $100 of revenue as net profit.
Cash quality
0.98×Cash from Krystal Biotech, Inc.'s business was 0.98× its reported profit in the year to Dec 2025 — less cash came in than the profit reported.
Cash vs debt
Net cashKrystal Biotech, Inc. held $818 M more cash than debt (net cash) at Dec 2025.
Questions
What is Krystal Biotech, Inc.'s P/E ratio?
Investors pay $40.1 for every $1 of Krystal Biotech, Inc.'s yearly profit, higher than 73% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Krystal Biotech, Inc.: $9.5 B ÷ $1.4 B (30 Jun 2026) = 7.0.
What is Krystal Biotech, Inc.'s return on equity?
Krystal Biotech, Inc. earned 20.1% on its shareholders' money over the last year, higher than 90% of Healthcare companies in United States.
How much does Krystal Biotech, Inc. owe compared with what it owns?
Krystal Biotech, Inc. owes $0.09 for every $1 it owns (low), lower than 88% of Healthcare companies in United States.
Does Krystal Biotech, Inc. pay a dividend?
No. Krystal Biotech, Inc. does not currently pay a dividend.
Is Krystal Biotech, Inc.'s revenue growing?
Revenue rose 34% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.